Previous 10 | Next 10 |
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the 23rd...
To further strengthen its balance sheet, Castle Biosciences (CSTL) has prepaid in full its outstanding term loan facility. “Following our recent successful equity financing, full prepayment of our outstanding debt signifies another step in fortifying our balance sheet,” sa...
Recent Equity Financing Contributes to Strong, Debt-Free Balance Sheet Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced it prepaid in full its outstand...
Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 600,000 shares, at a pu...
Castle Biosciences (CSTL) has priced its public offering of 4M common shares at $58.00/share, for expected gross proceeds of $232M.Underwriters' over-allotment is an additional 600K shares.Closing date is December 18.Previously: Castle Biosciences proposes public offering (Dec. 14) For furt...
Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the pricing of its underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $58.00 per share. The gross proceeds to Castle from the offering, before deducting underwriting discounts and comm...
Castle Biosciences (CSTL) proposes underwritten public offering to issue and sell $125M shares of its common stock. Underwriters' option to purchase up to an additional $18.75M shares. Size and terms yet to be finalised.Share -1.1% after hours For further details see: ...
Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell $125,000,000 of shares of its common stock. In connection with the offering, Castle expects to grant the unde...
Castle Biosciences (CSTL) +2% in premarket, has announced the publication of a clinical use study demonstrating that management decisions for patients diagnosed with melanoma were impacted by the use of DecisionDx-Melanoma, company's gene expression profile prognostic test, inc...
Study published in Future Oncology Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a clinical use study demonstrating that manageme...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at ...
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...